Studying why leukemia stops responding to venetoclax
Collects samples and records from adults with relapsed or refractory chronic lymphocytic leukemia on venetoclax.
Plain-language title generated from the registry record
Registry title: Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Key facts
- Where
- Amiens, Besançon, Bobigny, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier, Nancy, Paris, Pessac, Reims, and Toulouse, FranceSee the 14 sites
Where in France
- CHU D'amiensAmiens, FranceNot yet recruiting
- CHU de BesançonBesançon, FranceNot yet recruiting
- Hopital AvicenneBobigny, FranceNot yet recruiting
- CHU Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- CHU de Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- Chu GrenobleGrenoble, FranceNot yet recruiting
- CHRU de LilleLille, FranceNot yet recruiting
- Centre Leon BerardLyon, FranceNot yet recruiting
- CHU de MontpellierMontpellier, FranceNot yet recruiting
- CHU NancyNancy, FranceNot yet recruiting
- Hopital Pitie-SalpetriereParis, FranceNot yet recruiting
- Hopital Haut-LevequePessac, FranceNot yet recruiting
- CHU de ReimsReims, FranceTaking people
- IUCT OncopôleToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT05246345
- Record updated
- 9 January 2024
- Original description
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.Read full original descriptionShow less
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Inclusion: Age greater than or equal to 18 years old; chronic lymphocytic leukemia diagnosis according to iwCLL criteria; refractory and/or relapsed disease during or after venetoclax treatment; tumor samples available; Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome; Patients must be able to express their opposition to be enrolled in this study, if need be; Patients must be affiliated at the French Social Security system.
Exclusion: Patients of their legal guardians refusing to participate; -.